Vyvgart (efgartigimod)

Vyvgart (efgartigimod), by Argenx, is a treatment for adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive, the most common type of MG-causing antibody. It is designed to lower the number of circulating autoantibodies that wrongly attack healthy tissues.

Vyvgart was approved by the U.S. Food and Drug Administration in December 2021, and approval requests are under review by the European Medicines Agency (EMA) and regulators in Japan, with decisions expected in 2022. Argenx’s partner Zai Lab is planning to seek approval in China.

The therapy was given orphan drug status in both the U.S. and Europe.

How does Vyvgart work?

Antibodies are proteins that the immune system produces in response to foreign molecules invading the body. Also known as immunoglobulins, they fall into five classes: IgG, IgA, IgM, IgD, and IgE. Each class acts slightly differently and responds to different threats. Most antibodies in the blood and fluid that surround tissues and cells belong to the IgG class.

The self-reactive antibodies that contribute to MG development and progression also belong to the IgG class. In most patients, these autoantibodies target the acetylcholine receptor — a protein that binds to the neurotransmitter acetylcholine and plays a key role in nerve-muscle communication.

Normally, the binding of acetylcholine to its receptor signals muscles to contract. However, because the immune system attacks acetylcholine receptors in MG, acetylcholine cannot bind to them efficiently and nerve cells cannot send a strong signal to muscles, resulting in muscle weakness.

Normally, IgG antibodies circulating in the bloodstream are eventually broken down and recycled. A protein called neonatal Fc receptor (FcRn) helps to stabilize IgG antibodies and prevent this process. Vyvgart works by blocking FcRn, thereby increasing the rate at which IgG antibodies, including those driving MG, are broken down.

By lowering the levels of disease-driving antibodies, the therapy is expected to ease MG symptoms.

Vyvgart is not specific for antibodies that cause MG, however. The medication will also act on antibodies produced by the immune system in response to infections.

Vyvgart in clinical trials

In Phase 1 studies, researchers demonstrated that Vyvgart (formerly known as ARGX-113) had favorable safety and tolerability with different doses and dosing regimens. They also showed treatment led to promising reductions in the levels of disease-causing IgGs.

A Phase 2 study (NCT02965573) to assess the safety, efficacy, and pharmacological properties of Vyvgart in MG patients with generalized muscle weakness has been completed. Researchers administered Vyvgart in addition to patients’ current treatment, which included cholinesterase inhibitors, corticosteroids, or immunosuppressants.

Results showed that 75% of patients treated with Vyvgart had clinically and statistically significant improvements through at least six weeks, compared to 25% of those on placebo. Researchers reported no severe side effects.

A Phase 3 clinical called ADAPT (NCT03669588) evaluated Vyvgart’s safety and effectiveness in 167 adults with MG, including 129 who were positive for anti-AChR antibodies. Participants were randomized to either Vyvgart at 10 milligrams/kilogram (mg/kg) — administered in single weekly infusion cycles over four weeks, with a maximum of three rounds of treatment — or to a placebo, in addition to their current standard treatments, for 26 weeks (about six months).

Trial results showed that significantly more AChR-positive patients treated with Vyvgart showed clinically meaningful improvements in the Myasthenia Gravis Activities of Daily Living score, a measure of MG symptom severity, than those on a placebo (67.7% vs. 29.7%), meeting the trial’s main goal. The therapy was also associated with fast, deep, and durable responses among treated patients. Further analyses also showed that Vyvgart was superior to placebo among AChR-negative patients.

Treatment was generally well tolerated, with a safety profile comparable with that of placebo.

After completing ADAPT, most participants (about 91%) entered an open-label extension study called ADAPT+ (NCT03770403), in which all enrolled will be treated with Vyvgart for up to three years. Its main goals are to assess the treatment’s safety and tolerability for long-term use, and researchers expect to complete ADAPT+ in mid-2023.

Other details

Vyvgart is administered via hour-long infusions into the bloodstream. Patients initially receive four weekly infusions over the course of four weeks, with additional treatment cycles administered based on clinical response. The dosage per infusion is 10 mg/kg, or 1200 mg for patients who weight 120 kg (about 265 pounds) or more.

Its most common side effects (affecting 10% or more of patients) include respiratory tract infections, headache, and urinary tract infection. Allergic reactions to Vyvgart can occur, in which case treatment should be stopped and appropriate therapies given.

Because Vyvgart interacts with the immune system, it may make patients more susceptible to infections. It is recommended that treatment with Vyvgart be withheld if a patient is currently experiencing a serious infection. Vyvgart also may decrease the effectiveness of vaccines; as such, it is recommended that patients receive all age-appropriate vaccinations before initiating a new treatment cycle.

Argenx opened “My Vyvgart Path,” a program offering patients and clinicians in the U.S. support, product education, and financial assistance information, among other resources.

 

Last updated: Jan. 13, 2022, by Marisa Wexler MS

 


Myasthenia Gravis News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

2021 Myasthenia Gravis Survey Results

BioNews Survey Infographic

Myasthenia Gravis News conducted a survey from Feb. 11-March 28 to gain greater insight into the characteristics of the MG community and disease management. Results of the survey have now been published. Click on the image to view the infographic, and click here to read the story.